Af­ter a bruis­ing year, Aeter­na Zen­taris inks a $24M up­front US pact for growth hor­mone as­set

Over the past year Aeter­na Zen­taris $AEZS has watched its lead drug go down in flames on a failed Phase III tri­al, gone back to hunt an ap­proval for its old lead pro­gram — which had al­so failed — and got in­to a knock down and drag out fight with its ex-CEO over al­le­ga­tions he was try­ing to pur­loin their key re­main­ing as­set.

To­day, the com­pa­ny is an­nounc­ing that it’s hand­ing off US and Cana­di­an rights to Macrilen (maci­more­lin) — its sole as­set out­side of pre­clin­i­cal de­vel­op­ment — in ex­change for a $24 mil­lion cash up­front and $179 mil­lion in mile­stones, in­clud­ing a $5 mil­lion bonus for a pe­di­atric ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.